Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma The BASALT Randomized Controlled Trial

作者：Calhoun William J^*; Ameredes Bill T; King Tonya S; Icitovic Nikolina; Bleecker Eugene R; Castro Mario; Cherniack Reuben M; Chinchilli Vernon M; Craig Timothy; Denlinger Loren; DiMango Emily A; Engle Linda L; Fahy John V; Grant J Andrew; Israel Elliot; Jarjour Nizar; Kazani Shamsah D; Kraft Monica; Kunselman Susan J; Lazarus Stephen C; Lemanske Robert F Jr; Lugogo Njira; Martin Richard J; Meyers Deborah A; Moore Wendy C; Pascual Rodolfo

来源：Journal of the American Medical Association, 2012, 308(10): 987-997.

DOI：10.1001/2012.jama.10893

Context No consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma. Approaches include adjustment at outpatient visits guided by physician assessment of asthma control (symptoms, rescue therapy, pulmonary function), based on exhaled nitric oxide, or on a day-to-day basis guided by symptoms. %26lt;br%26gt;Objective To determine if adjustment of inhaled corticosteroid therapy based on exhaled nitric oxide or day-to-day symptoms is superior to guideline-informed, physician assessment-based adjustment in preventing treatment failure in adults with mild to moderate asthma. %26lt;br%26gt;Design, Setting, and Participants A randomized, parallel, 3-group, placebo-controlled, multiply-blinded trial of 342 adults with mild to moderate asthma controlled by low-dose inhaled corticosteroid therapy (n = 114 assigned to physician assessment-based adjustment [101 completed], n = 115 to biomarker-based [exhaled nitric oxide] adjustment [92 completed], and n = 113 to symptom-based adjustment [97 completed]), the Best Adjustment Strategy for Asthma in the Long Term (BASALT) trial was conducted by the Asthma Clinical Research Network at 10 academic medical centers in the United States for 9 months between June 2007 and July 2010. %26lt;br%26gt;Interventions For physician assessment-based adjustment and biomarker-based (exhaled nitric oxide) adjustment, the dose of inhaled corticosteroids was adjusted every 6 weeks; for symptom-based adjustment, inhaled corticosteroids were taken with each albuterol rescue use. %26lt;br%26gt;Main Outcome Measure The primary outcome was time to treatment failure. %26lt;br%26gt;Results There were no significant differences in time to treatment failure. The 9-month Kaplan-Meier failure rates were 22% (97.5% CI, 14%-33%; 24 events) for physician assessment-based adjustment, 20% (97.5% CI, 13%-30%; 21 events) for biomarker-based adjustment, and 15% (97.5% CI, 9%-25%; 16 events) for symptom-based adjustment. The hazard ratio for physician assessment-based adjustment vs biomarker-based adjustment was 1.2 (97.5% CI, 0.6-2.3). The hazard ratio for physician assessment-based adjustment vs symptom-based adjustment was 1.6 (97.5% CI, 0.8-3.3). %26lt;br%26gt;Conclusion Among adults with mild to moderate persistent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-based or symptom-based adjustment of inhaled corticosteroids was not superior to physician assessment-based adjustment of inhaled corticosteroids in time to treatment failure.

• 出版日期2012-9-12